Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biocare intends to make a strategic equity partnership of 30.4% in Gate2Brain. The investment of Euro 7 million includes cash infusion of Euro 0.5...
Pharmaceutical
Marksans Pharma to acquire Netherlands-based QliniQ B.V.
Marksans Pharma announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales...
True North buys 25% stake in pharma co Embio
Homegrown private equity firm True North will acquire a minority stake in Embio Ltd, a regulated markets-focused manufacturer of Active Pharmaceutical Ingredients (APIs), True North announced on Wednesday. According to...
Government okays Skymap Pharmaceuticals’ Rs 121-cr bid to buy IMPCL
The government has approved strategic sale of Indian Medicines Pharmaceutical Corporation Ltd (IMPCL) to Skymap Pharmaceuticals Pvt Ltd for over Rs 121 crore, the finance ministry said on Tuesday. The government had...
Lantheus weighs potential $7 billion sale after Curium’s offer, Bloomberg News reports
Radiopharmaceutical-focused company Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on...
HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030
HAB Pharma and Signature Phytochemicals have completed a merger through a slump sale, bringing both companies under a single consolidated entity. Finalized in March 2026, the merger was undertaken to streamline...
NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings
The NCLAT has allowed an appeal by Lyka Labs, overturning a previous order from the NCLT that had rejected its insolvency plea against Modi Lifecare Industries due to unpaid royalties stemming from a technical guidance...
Italy’s Angelini to buy US Catalyst Pharma in $4.1 billion state-backed deal
Angelini Pharma said on Thursday that it would acquire U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker’s entry into the U.S. pharmaceutical market. The...
LEO Pharma to buy U.S. drug developer Replay for $50 million upfront
Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic skin diseases to its dermatology...
Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 crore
Quadria Capital is among 4-5 private equity investors evaluating a potential acquisition of a controlling 80-85% stake in Samarth Lifesciences, said people familiar with the matter. A deal could value the manufacturer...
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is...
Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. A deal could be reached as soon as Monday and could...
